News
A new study presented today at the 41st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) ...
The global digital musculoskeletal (MSK) care market is poised for significant expansion, with an anticipated CAGR of 18-20% ...
A pairing of two experimental drugs inhibits tumor growth and blocks drug-induced resistance in ovarian cancer, according to ...
News-Medical.Net on MSN5d
XPR1 silencing enhances immune response and reduces ovarian tumor growthA recent study published in Genes & Diseases reveals a novel role of XPR1 in promoting ovarian cancer growth by regulating ...
News-Medical.Net on MSN4d
New combination therapy inhibits tumor growth and blocks drug-induced resistance in ovarian cancerA pairing of two experimental drugs inhibits tumor growth and blocks drug-induced resistance in ovarian cancer, according to ...
2don MSN
Genetic testing revealed that she was positive for BRCA1, a genetic mutation that increases one’s risk of breast and ovarian ...
New research reveals PD-L1 expression enhances survival in advanced ovarian cancer, linking it to homologous recombination ...
US ovarian cancer mortality rates declined from 1999 to 2020, but significant disparities remain across age, race, and geographic regions, highlighting the need for targeted public health efforts.
ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback